FDA Publishes Guidance on CMC Changes to an Approved Application
The final guidance document is intended to help determine which reporting category is appropriate for a change in CMC information to an approved biologics application.
FDA issued final guidance on June 21, 2021 to help applicants of certain licensed biological products to determine the appropriate reporting category for a change in chemistry, manufacturing, and controls (CMC) information to an approved biologics license application (BLA). The guidance document includes general and administration information for evaluating and reporting changes and reporting categories based on a tiered-reporting system. The final guidance supersedes the July 1997 guidance, Guidance for Industry: Changes to an Approved Application: Biological Products.
Specifically, the guidance details reporting categories such as Prior Approval Supplement (PAS), Changes Being Effected in 30 Days/Changes Being Effected Supplements (CBE30/CBE), and Annual Report. The assessment of a change by the applicant and by FDA is also discussed. The document also provides the requirements for submitting changes to the agency and recommendations for reporting categories. Special considerations discussed in the document include process parameter changes and changes in raw materials suppliers.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
